What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics

27/09/2015 - 1 minute

Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics

 

Tuesday: the Francis Crick Institute announced its application to conduct new research on human embryos

 

Wednesday: Israeli NovoCure announced an IPO on NASDAQ with a target of €170M

 

Thursday: Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy

 

Friday: in a successful phase III trial, the Amgen biosimilar showed full-efficacy equivalent to Roche’s Avastin

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!